demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID-19 prophylaxis (excluding children)
Non replicating viral vector
Janssen AD26 vaccine (JNJ-78436735) ENSEMBLE ...
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) ComFluCOV ... ChAdOx1 phase 3 ... COV005

58 studies excluded by filtering options 0

4830 NCT04276896, 0 2300excludednot a RCTrisk of bias not avaialble
4992 Candidate COVID-19 Vaccine (COV001), 2020 210excludedrisk of bias not avaialble
5682 AstraZeneca Oxford COV003 phase 3, 0 110risk of bias not avaialble
5690 CanSino phase 3, 2021 010selection pending
5810 AstraZeneca phase 3 US (D8110C00001), 2021 110risk of bias not avaialble
5955 RESIST (Sputnik V Gamaleya Research Institute Russia), 2020 113high risk of bias
6049 CanSino phase 2 (Zhu), 2020 110risk of bias not avaialble
6103 Folegatti, 2020 010selection pending
6444 Barrett, 2020 200excludedrisk of bias not avaialble
6484 Sadoff, 2021 110risk of bias not avaialble
6664 Scotland cohort, 0 1100not a RCTrisk of bias not avaialble
6904 HORIZON 1, 0 0310selection pending
6949 Pawlowski, 2021 1130not a RCTrisk of bias not avaialble
6965 Bernal (PHE, 19th February 2021), 2021 1130not a RCTrisk of bias not avaialble
6975 Corchado-Garcia, 2021 0130selection pending
7012 Pottegard, 2021 1154not a RCThigh risk of bias
7017 John, 2021 000selection pending
7022 Bernal, 0 1130not a RCTrisk of bias not avaialble
7939 Com-COV, 2021 110risk of bias not avaialble
8160 Babamahmoodi, 2021 2990excludednot a RCTrisk of bias not avaialble
8162 Johnson and Johnson, 2021 000selection pending
8252 Edward (Vaxzevria), 2021 1134not a RCThigh risk of bias
8267 Burn (Vaxzevria), 2021 1134not a RCThigh risk of bias
8295 Sisonke (JNJ South Africa heathworkers), 0 0130selection pending
9070 Tobaiqy M, 2021 2320excludednot a RCTrisk of bias not avaialble
9173 Sisonke 2 (booster), 2021 1200not a RCTrisk of bias not avaialble
9216 Sultan, 2022 0120selection pending
9221 Bonelli, 2022 000selection pending
9232 Com-COV2, 2022 110risk of bias not avaialble
9234 Asano, 2022 110risk of bias not avaialble
9244 Richardson, 2022 000selection pending
9268 Nguyen, 2021 0110selection pending
9274 MixNMatch Study, 2021 1100not a RCTrisk of bias not avaialble
9296 Hippisley-Cox, 2021 1120not a RCTrisk of bias not avaialble
9297 Simpson (ChAdOx1), 2021 1120not a RCTrisk of bias not avaialble
9298 Fengcai, 2021 110risk of bias not avaialble
9302 Kulkarni, 2021 110risk of bias not avaialble
9311 Li J, 2022 110risk of bias not avaialble
9312 Reindl-Schwaighofer, 2021 110risk of bias not avaialble
9313 EPIPHARE (Vaxzevria), 2022 1120not a RCTrisk of bias not avaialble
9336 NCT04540419, 0 010selection pending
9343 EPIPHARE (Janssen), 2022 1120not a RCTrisk of bias not avaialble
9356 AstraZeneca Oxford pooled analysis (COV003, COV001, COV002, COV005)_safety, 2020 110risk of bias not avaialble
9360 Husby (Astra), 2021 1120not a RCTrisk of bias not avaialble
9361 Husby (janssen), 2021 1120not a RCTrisk of bias not avaialble
9370 Kanokudom, 2022 000selection pending
9376 Nanthapisal, 2022 210excludedrisk of bias not avaialble
9404 Botton (EPI-PHARE), 2022 1120not a RCTrisk of bias not avaialble
9467 Clemens, 2021 0100selection pending
9486 Pitisuttithum, 2022 010selection pending
9492 Patone, 2021 1120not a RCTrisk of bias not avaialble
9493 Barchuk, 2022 000selection pending
9580 Sisonke study (bekker), 2022 000selection pending
9614 Rearte, 2022 0120selection pending
9614 Rearte, 2022 0120selection pending
9808 Nabirova, 2022 1130not a RCTrisk of bias not avaialble
10189 AstraZeneca phase 3 US (D8110C00001) 6 month follow up, 2021 110risk of bias not avaialble
10190 Valim, 2022 000selection pending